Fennec Pharmaceuticals
Tracked across 4 events · 26 articles · First seen Apr 07, 2026 · Last active Jun 15, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Fennec Pharmaceuticals announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate PEDMARK in AYA and adult patients. This expands the potential market for PEDMARK and could lead to label expansion.
Apr 07, 2026 · 7 articles
Business
Impact: Fennec Pharmaceuticals announced it will release its first quarter 2026 financial results and host a conference call to discuss them.
May 07, 2026 · 6 articles
Business
Impact: Fennec Pharmaceuticals reported strong Q1 2026 financial results with a 73% year-over-year increase in net revenues, driven by the growing adoption of its product PEDMARK. The company also initiated a new clinical study for PEDMARK and will present abstracts at the ASCO Annual Meeting, indicating positive business momentum and potential for sustained growth.
May 14, 2026 · 6 articles
Business
Impact: Fennec Pharmaceuticals granted stock options to new employees as an inducement for their employment, which is a common practice to attract talent and align employee interests with company performance.
May 18, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Fennec Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard